

Product datasheet for **CF809937**

p16INK4A (CDKN2A) Mouse Monoclonal Antibody [Clone ID: OTI4E11]

Product data:

Product Type:	Primary Antibodies
Clone Name:	OTI4E11
Applications:	WB
Recommended Dilution:	WB 1:500~2000
Reactivity:	Human, Mouse
Host:	Mouse
Isotype:	IgG1
Clonality:	Monoclonal
Immunogen:	Full length human recombinant protein of human CDKN2A (NP_000068) produced in E.coli.
Formulation:	Lyophilized powder (original buffer 1X PBS, pH 7.3, 8% trehalose)
Reconstitution Method:	For reconstitution, we recommend adding 100uL distilled water to a final antibody concentration of about 1 mg/mL. To use this carrier-free antibody for conjugation experiment, we strongly recommend performing another round of desalting process. (OriGene recommends Zeba Spin Desalting Columns, 7KMWCO from Thermo Scientific)
Purification:	Purified from mouse ascites fluids or tissue culture supernatant by affinity chromatography (protein A/G)
Conjugation:	Unconjugated
Storage:	Store at -20°C as received.
Stability:	Stable for 12 months from date of receipt.
Predicted Protein Size:	16.4 kDa
Gene Name:	cyclin dependent kinase inhibitor 2A
Database Link:	NP_000068 Entrez Gene 12578 Mouse Entrez Gene 1029 Human Q8N726
Synonyms:	ARF; CDK4I; CDKN2; CMM2; INK4; INK4A; MLM; MTS-1; MTS1; P14; P14ARF; P16; P16-INK4A; P16INK4
Protein Families:	Druggable Genome




[View online »](#)


Protein Pathways:

Bladder cancer, Cell cycle, Chronic myeloid leukemia, Glioma, Melanoma, Non-small cell lung cancer, p53 signaling pathway, Pancreatic cancer, Pathways in cancer

Product images:



HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY CDKN2A ([RC220937], Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-CDKN2A (1:2000). Positive lysates [LY400022] (100ug) and [LC400022] (20ug) can be purchased separately from OriGene.



Western blot analysis of extracts (35ug) from 3 different cell lines by using anti-CDKN2A monoclonal antibody (1:500).